Halabi Jessica El, Hariri Essa, Pack Quinn R, Guo Ning, Yu Pei-Chun, Patel Niti G, Imrey Peter B, Rothberg Michael B
Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio.
Division of Cardiovascular Medicine, Baystate Medical Center, Springfield, MA.
Am J Med Open. 2023 Jun;9. doi: 10.1016/j.ajmo.2022.100025. Epub 2023 May 19.
Patients admitted with pneumonia and heart failure (HF) have increased mortality and cost compared to those without HF, but it is not known whether outcomes differ between systolic and diastolic HF. Management of concomitant pneumonia and HF is complicated because HF treatments can worsen complications of pneumonia.
This is a retrospective cohort study from the Premier Database among patients admitted with pneumonia between 2010-2015. Patients were categorized based on systolic, diastolic, and combined HF using ICD-9 codes. The primary outcome was in-hospital mortality. Secondary outcomes included use of HF medications, length of stay, cost, intensive care unit (ICU) admission, as well as use of invasive mechanical ventilation (IMV), vasopressors and inotropes. Multivariable logistic regression was used to describe associations of these outcomes with type of HF.
Of 123,211 patients with pneumonia and HF, 41,196 (33.4%) had systolic HF, 69,982 (56.8%) diastolic HF, and 12,033 (9.8%) had combined HF. Compared to patients with diastolic HF, after multivariable adjustment systolic HF was associated with higher in-hospital mortality (OR 1.15; 95% CI:1.11-1.20), ICU admission, and use of IMV and vasoactive agents, but not with increased length of stay or cost. Among patients with systolic HF, 80% received a loop diuretic, 72% a beta blocker, 48% angiotensin converting enzyme inhibitor or angiotensin receptor blocker, and 12.5% a mineralocorticoid receptor antagonist.
Systolic HF is associated with added risk in pneumonia compared to diastolic HF. There may also be an opportunity to optimize medications in systolic HF prior to discharge.
与无心力衰竭(HF)的肺炎患者相比,合并肺炎和心力衰竭的患者死亡率更高,费用更高,但尚不清楚收缩性心力衰竭和舒张性心力衰竭患者的预后是否存在差异。同时合并肺炎和心力衰竭的治疗较为复杂,因为心力衰竭的治疗可能会加重肺炎的并发症。
这是一项基于Premier数据库的回顾性队列研究,研究对象为2010年至2015年间因肺炎入院的患者。根据国际疾病分类第九版(ICD-9)编码,将患者分为收缩性心力衰竭、舒张性心力衰竭和混合性心力衰竭。主要结局为住院死亡率。次要结局包括心力衰竭药物的使用、住院时间、费用、重症监护病房(ICU)入住情况,以及有创机械通气(IMV)、血管升压药和正性肌力药物的使用。采用多变量逻辑回归分析来描述这些结局与心力衰竭类型之间的关联。
在123,211例合并肺炎和心力衰竭的患者中,41,196例(33.4%)为收缩性心力衰竭,69,982例(56.8%)为舒张性心力衰竭,12,033例(9.8%)为混合性心力衰竭。多变量调整后,与舒张性心力衰竭患者相比,收缩性心力衰竭患者的住院死亡率更高(比值比[OR]1.15;95%置信区间[CI]:1.11-1.20),入住ICU的几率更高,IMV和血管活性药物的使用几率更高,但住院时间和费用并未增加。在收缩性心力衰竭患者中,80%使用了袢利尿剂,72%使用了β受体阻滞剂,48%使用了血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂,12.5%使用了盐皮质激素受体拮抗剂。
与舒张性心力衰竭相比,收缩性心力衰竭会增加肺炎患者的风险。在出院前,收缩性心力衰竭患者可能也有机会优化药物治疗。